Nkarta Inc (NKTX)
Nkarta, Inc. is a clinical-stage biopharmaceutical company focused on developing natural killer cell therapies for cancer and autoimmune diseases. Its lead candidate, NKX019, is a chimeric antigen receptor natural killer, or CAR NK, therapy designed to target the CD19 antigen and is being evaluated in Phase 1 studies for lupus nephritis, systemic sclerosis, idiopathic inflammatory myopathy, ANCA-associated vasculitis, systemic lupus erythematosus, and myasthenia gravis. The company also maintains a research collaboration with CRISPR Therapeutics AG. Nkarta was incorporated in 2015 and is based in South San Francisco, California. The listed security is common stock on the NASDAQ exchange under the symbol NKTX.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-NKTX
|
$3.57
|
36.7% Upside
|
Undervalued
|
$11.33
|
334.2% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 6, 2026
|
-1.9x
|
0.7x
|
—
|
183.9 M
|
32.021 M
|
29.0%
|
84.5%
|
-1.6
|
—
|
88.4%
|
